JPS6043351B2 - 老人医学的薬剤の製法 - Google Patents
老人医学的薬剤の製法Info
- Publication number
- JPS6043351B2 JPS6043351B2 JP49009826A JP982674A JPS6043351B2 JP S6043351 B2 JPS6043351 B2 JP S6043351B2 JP 49009826 A JP49009826 A JP 49009826A JP 982674 A JP982674 A JP 982674A JP S6043351 B2 JPS6043351 B2 JP S6043351B2
- Authority
- JP
- Japan
- Prior art keywords
- theophylline
- compound
- acetate
- compounds
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title description 8
- 229940079593 drug Drugs 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000002253 acid Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000002921 anti-spasmodic effect Effects 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 229960001789 papaverine Drugs 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OMFNSKIUKYOYRG-UHFFFAOYSA-N 1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-3,4-dihydro-2h-isoquinoline Chemical compound C1=C(OCC)C(OCC)=CC=C1C=C1C2=CC(OCC)=C(OCC)C=C2CCN1 OMFNSKIUKYOYRG-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-M 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetate Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC([O-])=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- -1 methoxy, ethoxy, propoxy Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU2251/CI-1333 | 1973-01-25 | ||
| HUCI1333A HU167246B (en, 2012) | 1973-01-25 | 1973-01-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5046818A JPS5046818A (en, 2012) | 1975-04-25 |
| JPS6043351B2 true JPS6043351B2 (ja) | 1985-09-27 |
Family
ID=10994468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP49009826A Expired JPS6043351B2 (ja) | 1973-01-25 | 1974-01-24 | 老人医学的薬剤の製法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4035366A (en, 2012) |
| JP (1) | JPS6043351B2 (en, 2012) |
| BE (1) | BE810145A (en, 2012) |
| CA (1) | CA1018160A (en, 2012) |
| DE (1) | DE2403122A1 (en, 2012) |
| ES (1) | ES422694A1 (en, 2012) |
| FR (1) | FR2221134B1 (en, 2012) |
| GB (1) | GB1417542A (en, 2012) |
| HU (1) | HU167246B (en, 2012) |
| IL (1) | IL44056A (en, 2012) |
| SU (1) | SU506298A3 (en, 2012) |
| YU (1) | YU19274A (en, 2012) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS614663U (ja) * | 1984-06-13 | 1986-01-11 | 日輪ゴム工業株式会社 | ゲ−ム用ボ−ル |
| JPS6384261U (en, 2012) * | 1986-11-19 | 1988-06-02 | ||
| JPS63154049U (en, 2012) * | 1987-03-28 | 1988-10-11 | ||
| JPS63160864U (en, 2012) * | 1987-04-08 | 1988-10-20 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2368277A1 (fr) * | 1976-10-21 | 1978-05-19 | Sobio Lab | Nouveaux derives hydrogenes de l'isoquinoleine, ayant une activite vasoactive et spasmolytique |
| FR2377385A2 (fr) * | 1977-01-12 | 1978-08-11 | Sobio Lab | Nouveaux derives hydrogenes de l'isoquinoleine, ayant une activite vasoactive et spasmolytique |
| HU194179B (en) * | 1985-10-03 | 1988-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of 1-/3',4'-dietoxi-benzil/-1,6,7-dietoxi-3,4-dihydro-izoquinolinine-teophilin-7-acetate and their new cristallic monohydrate |
| HU197207B (en) * | 1985-12-04 | 1989-03-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical comprising 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydro-isoquinolinium-theophylline-7-acetate or its monohydrate as active ingredient |
| HUT60926A (en) | 1991-04-12 | 1992-11-30 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition suitable for reducing or preventing increased thrombocyte-aggregation capability |
| JP3276762B2 (ja) * | 1993-12-28 | 2002-04-22 | 日本臓器製薬株式会社 | イソキノリン誘導体を含有する医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2975M (fr) * | 1963-09-02 | 1964-11-30 | Agrologique Francaise Soc | Nouveaux médicaments a base de dérivés alcaloides de l'acide théophylline-acétique. |
| FR1369374A (fr) * | 1963-04-26 | 1964-08-14 | Agrologique Francaise Soc | Dérivés alcaloïdes de l'acide théophylline-acétique et leur procédé de fabrication |
| FR3625M (fr) * | 1964-05-14 | 1965-10-18 | Gerda Lab | Médicament constitué par des dérivés de l'acide théophylline-acétique. |
-
1973
- 1973-01-25 HU HUCI1333A patent/HU167246B/hu unknown
-
1974
- 1974-01-22 US US05/435,591 patent/US4035366A/en not_active Expired - Lifetime
- 1974-01-22 IL IL44056A patent/IL44056A/en unknown
- 1974-01-23 DE DE2403122A patent/DE2403122A1/de active Granted
- 1974-01-23 FR FR7402194A patent/FR2221134B1/fr not_active Expired
- 1974-01-23 ES ES422694A patent/ES422694A1/es not_active Expired
- 1974-01-24 JP JP49009826A patent/JPS6043351B2/ja not_active Expired
- 1974-01-24 SU SU1999306A patent/SU506298A3/ru active
- 1974-01-24 GB GB329974A patent/GB1417542A/en not_active Expired
- 1974-01-24 CA CA190,817A patent/CA1018160A/en not_active Expired
- 1974-01-25 BE BE140161A patent/BE810145A/xx not_active IP Right Cessation
- 1974-01-25 YU YU00192/74A patent/YU19274A/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS=1970 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS614663U (ja) * | 1984-06-13 | 1986-01-11 | 日輪ゴム工業株式会社 | ゲ−ム用ボ−ル |
| JPS6384261U (en, 2012) * | 1986-11-19 | 1988-06-02 | ||
| JPS63154049U (en, 2012) * | 1987-03-28 | 1988-10-11 | ||
| JPS63160864U (en, 2012) * | 1987-04-08 | 1988-10-20 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES422694A1 (es) | 1976-09-01 |
| BE810145A (fr) | 1974-05-16 |
| IL44056A (en) | 1977-01-31 |
| DE2403122A1 (de) | 1974-08-01 |
| JPS5046818A (en, 2012) | 1975-04-25 |
| FR2221134B1 (en, 2012) | 1976-09-03 |
| HU167246B (en, 2012) | 1975-09-27 |
| SU506298A3 (ru) | 1976-03-05 |
| YU19274A (en) | 1983-01-21 |
| US4035366A (en) | 1977-07-12 |
| GB1417542A (en) | 1975-12-10 |
| AU6477874A (en) | 1975-07-24 |
| DE2403122C2 (en, 2012) | 1990-03-22 |
| FR2221134A1 (en, 2012) | 1974-10-11 |
| CA1018160A (en) | 1977-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3997666A (en) | 1-[3-(Naphth-1-yloxy)-2-hydroxypropvl]-piperazine compounds and therapeutic compositions | |
| JPS62215527A (ja) | アルツハイマー病治療薬 | |
| JPS6256143B2 (en, 2012) | ||
| JPS6028979A (ja) | イミダゾキナゾリン類化合物 | |
| JPS6043351B2 (ja) | 老人医学的薬剤の製法 | |
| JPS6230780A (ja) | １，７−ナフチリジン誘導体及びこれを含有する薬剤 | |
| US3931212A (en) | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives | |
| JPH04264030A (ja) | 抗喘息剤 | |
| EP0273375A2 (en) | Propiophenone derivatives for treatment of pollakiuria (frequency urination) | |
| JPS6031833B2 (ja) | 新規な２０，２１↓−ジノルエブルナメニン誘導体、その製造法及び製薬組成物 | |
| EP0194665A1 (en) | beta-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives | |
| US3975524A (en) | 3-Piperazino-isoquinolines and salts thereof | |
| EP0448029A2 (en) | Novel pharmaceutical uses of forskolin derivatives | |
| US3840539A (en) | Phthalazine derivatives | |
| CA1133913A (en) | N-(1-methyl-2-pyrrolidinyl-methyl)-2,3- dimethoxy-5-methylsulphamoyl benzamide and its derivatives, their preparation processes and their use in the treatment of disorders of the lower urinary apparatus | |
| US4315003A (en) | Compositions containing azo compounds and use thereof for therapeutic treatment | |
| CN116444377A (zh) | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 | |
| JPS63104960A (ja) | α−［（フェニルメトキシ）メチル］ピリジンアルカノール誘導体 | |
| US3629443A (en) | Therapeutic composition containing a mandelamidine derivative | |
| US3906107A (en) | Aminoalkyl sulfate esters with diuretic activity | |
| US4263316A (en) | N-(1-Methyl-2-pyrrolidinylmethyl)-2,3-dimethoxy-5-methylsulfamoyl benzamide and its derivatives, methods of preparing them and their application to the treatment of troubles of the lower part of the body | |
| US2899358A (en) | Process | |
| US4745118A (en) | Substituted quinazoline-3-oxides providing pharmacological activity | |
| US4107172A (en) | Uricosuric diuretic composition | |
| US3436458A (en) | Antispasmodic and gastric antisecretory compositions containing rho-phenylphenacyl derivatives of 1-hyoscyamine and d,1-tropylatropine |